AI assistant
INVENTURUS KNOWLEDGE SOLUTIONS LIMITED Investor Presentation 2026
60278_rns_2026-05-13_9879be90-9504-437c-821e-868c61940f4a.pdf
Investor Presentation
Open in viewerOpens in your device viewer
IKS HEALTH
May 13, 2026
BSE Limited
The Listing Department
Phiroze Jeejeebhoy Towers
25th Floor, Dalal Street
Fort, Mumbai 400 001
Maharashtra, India
BSE Scrip Code: 544309
Nacional Stock Exchange of India Limited
The Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051
Maharashtra, India
NSE Symbol: IKS
Dear Sir/Ma’am,
Sub: Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith investor presentation on the financial results of the Company for the quarter and year ended March 31, 2026.
The said presentation are also being uploaded on the website of the Company at the https://ikshealth.com/investor-relations/
Request you to take it on record and disseminate the same on your website.
Thanking you.
Yours sincerely,
For Inventurus Knowledge Solutions Limited
Sameer Chavan
Company Secretary and Compliance Officer
Membership No. F7211
Encl: As above
M/s. Inventurus Knowledge Solutions Limited
801, Building No. 5 & 6, 8th Floor, Mindspace Business Park (SEZ), Thane - Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India. | Board: +91 22 3071 1100 | Fax: 91 22 6646 6879 | [email protected] | www.ikshealth.com
Registered Address: 801, Building No. 5 & 6, 8th Floor, Mindspace Business Park (SEZ), Thane - Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India. CIN: L72200MH2006PLC337651
IKS Health
Q4 FY 26 Investor Presentation
IKS
Disclaimer
This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the statements themselves. Such statements comprise the company's current visibility on market movements, client discussions, and related factors. Inventurus Knowledge Solutions Limited does not assume an obligation to update or revise any forward-looking statements.
LKS
IKS Health - a comprehensive healthcare enablement platform empowering provider organizations
| US$5tn
US Healthcare
Expenditure (CY2024) | US$260bn /
US$34bn
TAM / Outsourced Market
(CY2023) | 8% / 12%
TAM / Outsourced Market
CAGR (2023-2028E) |
| --- | --- | --- |
| 600+/700+
Healthcare Organizations
Q4 26/Q4 25 | 90%+
Revenues from Repeat
Customers | 5+ Years
Top 10 / Top 5 Clients
Average Vintage
(As of Mar 31, 2026) |
| 13,331 / 1,981
Employees / Clinically
trained staff
(As of Mar 31, 2026) | 550
Technology Focused
Employees
(As of Mar 31, 2026) | 66
Sales & Marketing
Employees
(As of Mar 31, 2026) |
The only Comprehensive platform that delegates all chores across the patient journey
Adding a technology-enabled layer to 'care delivery pyramid' to help Physician Enterprises achieve optimized revenue and reduced expenses
IKS
Note: Numbers Rounded off to nearest Integer / percent; 1. Source: Zinnov Report; 2. TAM- Total Addressable Market for RCM, VBC, Patient, Coding and Client Services. 3. Repeat clients refers to clients who availed our platform or solutions during the previous period, and revenue generated from such clients are calculated for the relevant period
IKS Health: 5 Strategic Pillars of execution
AI-native, Agentic Platform Manifest
- Launched interconnected agents, exhibits for autonomous Clinical Documentation, Coding and Peer Authorization
- Launched Scribble Now, launching multi-variant scribble
- Novelized Autonomous Coding for two medical specialities, optimizing and expanding to other specialties
- MyCareHub – Multi agent presentation across patient engagement features
AQuity Acquisition Integration & Optimization
- Integration ☑☑☑
- Margin expansion ☑☑
- Cross Sell motion ☑
Establishing Leadership across features; while driving platform uniqueness
-
1 in AI-driven RCM and Medical coding by Blackbook
-
1 in Clinical documentation by Blackbook and KLAS
- Top performer in ambulatory RCM by KLAS
Differentiated Growth Market Strategy
- Secured marquee platform wins in Independent Groups and Small/Medium Health Systems
- Point solution Land and Expand in large Health Systems
Evolution Towards an Outcome-Oriented Company
- Cultivating outcome-oriented deals that drive stickiness and additional economic pools
- Building capability to drive outcomes
- $3 million NEVA earned in Palomar in first year despite staggered implementation
IKS
☑☑☑ Indicates progress using a 3-point scale
Awards and Recognition
ET Edge Best Organisations for Women 2026
Financial Express AICONIC Award 2026
Best Use of AI in Healthcare & Lifesciences
IKS Health Virtual Care Assistant
IKS
Accelerating AI Initiatives
Partnership with Certilytics, an innovator in AI driven healthcare intelligence, to connect payer rules and provider workflows using agentic AI, human oversight, and unified action
Strategic acquihire of ThinkDTM, an AI-native product, strategy, and digital services company, including ThinkDTM Founder Tij Bedi and team of AI experts on patient access solutions portfolio.
Launched AI-driven revenue cycle management (RCM), audit-ready, autonomous coding engine delivering up to $95\%$ coding accuracy while reducing denials. The solution is integrated with Epic (available in Epic Connection Hub) and combines AI-driven code assignment with expert human review to deliver accurate, audit-ready codes from chart to claim.
Launched MyCareHub™, an agentic AI self-orchestrating platform that uses an active, aware and constant multi-agent behavioral algorithm to create an adaptive and autonomous patient engagement operating system, integrated with Epic (available in Epic Connection Hub)
I×S
IKS Health enables care transformation across the patient journey
IKS
7
Q4 - Strong growth while delivering continuous margin expansion
LKS
Key Deal Wins
IKS Health has entered a strategic multi-year full platform partnership with Holyoke Medical Center, a legacy Equity customer. This collaboration leverages AI-driven and human-led solutions to reduce administrative burden, lower costs, and drive new revenue for the hospital's financial stability and sustainable growth.
IKS Health has expanded the platform relationship to include development of advanced AI capabilities within the hospital environment to improve operational efficiencies.
Top 5 Health System
Expanded the existing Revenue Cycle Management (RCM) and Value-Based Care (VBC) partnership with a top 5 health system to encompass additional regions and states within the scope of IKS Services.
IKS
Q4 FY 26: Growing faster than market with improving margins
Revenue
INR Mn
PAT*
INR Mn
EBITDA
INR Mn
Adjusted PAT**
INR Mn
SIXTEEN
*PAT includes a #127 million non-recurring, non-cash write-off of unamortized debt cost, resulting from loan refinancing at favourable terms.
**Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition and write off of unamortized debt cost due to refinancing of existing loan on favourable terms both of which are non-cash expenses.
Q4 FY 26 - Improving EPS and maintaining high ROE
EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.
ROE %
Return on Equity is calculated as profit for the period divided by average equity balance during the period.
LKS
TENNESSEE
11
FY 26 - Strong growth while delivering continuous margin expansion
| Growth At Scale | Deep Client Relationships | Strong Margin Profile | Globally Diversified Workforce |
|---|---|---|---|
| INR 31,938 mn | |||
| Revenue from Operations | 450+ | ||
| Enterprise level customers | 34% | ||
| EBITDA | 13,331 | ||
| Total Employees | |||
| 20% | |||
| YoY growth in INR | INR mn 11,811/37% | ||
| Revenue from Top 10 customers | 23% | ||
| PAT Margin | 1,981 / 550 | ||
| Clinical /tech focussed employees | |||
| 15% | |||
| YoY growth in USD | 5.94 / 5.82 years | ||
| Top 10 / Top 5 Clients Average Vintage | 38%/48% | ||
| YoY growth in EBITDA/PAT | 45% | ||
| Women employees |
LKS
FY 26: Growing faster than market with improving margins
Revenue
INR Mn
EBITDA
INR Mn
19.9% YoY
7,911
29.7%
March 31, 2025
10,913
34.2%
March 31, 2026
38.0% YoY
PAT*
INR Mn
48.4% YoY
5,504
20.7%
March 31, 2025
8,087
25.3%
March 31, 2026
46.9% YoY
PAT includes a ₹127 million non-recurring, non-cash write-off of unamortized debt cost, resulting from loan refinancing at favourable terms.
*Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition and write off of unamortized debt cost due to refinancing of existing loan on favourable terms both of which are non-cash expenses.
LKS
REGION
FY 26 - Improving EPS and maintaining high ROE
EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.
ROE* %
31.4%
FY 26
Return on Equity is calculated as profit for the period divided by average equity balance during the period.
LKS LIECHTEN
*EPS and ROE includes a ₹127 million non-recurring, non-cash write-off of unamortized debt cost, resulting from loan refinancing at favourable terms.
FY 26 - Strong Cash Generation supporting growth aspirations
15
A Decade of Consistent Profitable Growth
INR Mn
SIXS
Financials - Summary INR millions
| Particulars | Q4 FY 25 | Q3 FY 25 | QoQ% | Q4 FY 25 | YoY% | FY 26 | FY 25 | YoY% |
|---|---|---|---|---|---|---|---|---|
| Revenue USD mn | 95 | 93 | 2.4% | 84 | 12.6% | 364 | 316 | 15.4% |
| Revenue | 8,577 | 8,150 | 5.2% | 7,240 | 18.5% | 31,938 | 26,640 | 19.9% |
| Other Income - Operating | - | - | 0.0% | 0.0% | 176 | -100.0% | ||
| Forex Gain/ (Loss) | 352 | 87 | 303.3% | (24) | -1587.4% | 627 | 38 | 1552.5% |
| Employee benefit expense excluding ESOP | 4,011 | 3,947 | 1.6% | 3,749 | 7.0% | 15,803 | 14,669 | 7.7% |
| Other Expenses | 1,743 | 1,362 | 28.0% | 1,089 | 60.1% | 5,379 | 3,997 | 34.6% |
| Adjusted EBITDA | 3,175 | 2,928 | 8.4% | 2,378 | 33.5% | 11,383 | 8,188 | 39.0% |
| Adjusted EBITDA % | 37.0% | 35.9% | 1.1% | 32.8% | 4.2% | 35.6% | 30.7% | 4.9% |
| ESOP Cost | 173 | 112 | 53.4% | 116 | 48.5% | 470 | 277 | 69.4% |
| EBITDA | 3,002 | 2,816 | 6.6% | 2,262 | 32.7% | 10,913 | 7,911 | 38.0% |
| EBITDA % | 35.0% | 34.6% | 0.5% | 31.2% | 3.8% | 34.2% | 29.7% | 4.5% |
| Finance cost* | 127 | 233 | -45.7% | 210 | -39.7% | 702 | 898 | -21.7% |
| Depreciation and amortisation | 341 | 320 | 6.3% | 283 | 20.2% | 1,242 | 1,127 | 10.2% |
| Interest income | 49 | 56 | -12.2% | 33 | 49.4% | 172 | 176 | -2.5% |
| Profit before exceptional items and tax | 2,584 | 2,318 | 11.5% | 1,801 | 43.5% | 9,141 | 6,063 | 50.8% |
| Profit before exceptional items and tax % | 30.1% | 28.4% | 1.7% | 24.9% | 5.2% | 28.6% | 22.8% | 5.9% |
| Tax expense | 470 | 460 | 2.1% | 323 | 45.5% | 1,834 | 1,202 | 52.5% |
| Profit for the period before Share of Associates | 2,114 | 1,857 | 13.8% | 1,478 | 43.0% | 7,308 | 4,861 | 50.3% |
| Profit for the period before Share of Associates % | 24.6% | 22.8% | 1.9% | 20.4% | 4.2% | 22.9% | 18.2% | 4.6% |
| Share of Profit/(Loss) from Associates (net of tax) | (54) | (24) | 125.7% | 0.0% | (92) | 0.0% | ||
| Profit for the period | 2,060 | 1,833 | 12.3% | 1,478 | 39.4% | 7,216 | 4,861 | 48.4% |
| Profit for the period % | 24.0% | 22.5% | 1.5% | 20.4% | 3.6% | 22.6% | 18.2% | 4.3% |
| Unamortised Debt Cost written off* | 127 | -100.0% | - | 0.0% | 127 | - | 0.0% | |
| Amortisation of Intangible assets | 210 | 194 | 8.3% | 168 | 24.8% | 744 | 643 | 15.8% |
| Adjusted Profit for the period | 2,269 | 2,154 | 5.4% | 1,646 | 37.9% | 8,087 | 5,504 | 46.9% |
| Adjusted Profit for the period % | 26.5% | 26.4% | 0.0% | 22.7% | 3.7% | 25.3% | 20.7% | 4.7% |
LKS LIFELICA
*The Company successfully refinanced its existing term loan at more favorable interest rates during Q3, FY 26. Consequently, the unamortized debt issuance costs associated with the original loan were written off as a one-time, non-cash expense. This charge is included within Finance cost as reported in the results.
Other KPI Metrics
| Particulars | FY 26 | FY 25 |
|---|---|---|
| Adjusted EBITDA per employee | 0.88 | 0.63 |
| Revenue from Top 10 customers INR mn | 11,811 | 9,230 |
| Contribution from Top 10 customers | 37.0% | 34.6% |
| Revenue from Top 5 customers INR mn | 6,856 | 5,828 |
| Contribution from Top 5 customers | 21.5% | 21.9% |
| Ageing of Top 10 clients (number of years) | 5.94 | 6.20 |
| Ageing of Top 5 clients (number of years) | 5.82 | 8.57 |
| FCF Yield | 84.9% | 56.7% |
| Clients with revenue >$1mn | 66 | 69 |
IKS
Strategic Growth
Proposed Acquisition of TruBridge
LKS
System of Action + System of Record → Operating System for Healthcare
Closed loop operating model
System of Record (EHR)
- Synthesizes data from all points of care
- Authoritative source of clinical truth
- Proprietary, longitudinal, structured clinical data
Data feed & capabilities needed from EHR
Critical needs for agentic AI orchestration
- Trusted, structured data source
- Proprietary AI training corpus
- Native backbone for workflows
- Deep clinical context
Actions / Outcomes feedback
System of Action
(Agentic AI powered Care Enablement Platform)
- Ingests, aggregates, normalizes, analyzes
- Converts data into actions, decisions, and revenue
- Orchestrates agentic AI workflows
Value created
Directly linking the System of Record and System of Action enables:
Elimination of middleware
- Reduced friction
- Lower latency
Single source of truth
- Automated data hygiene
- Reduction in errors
Seamless workflow integration
- Reduced Human involvement
AI optimization through continuous learning
Business implications
- Compounding value creation
- Multi-stream, deeply embedded recurring revenue stream
- Outcome/ Value-based contracts
- Long term structural advantage
IKS SYSTEMS
20
Strategic Acquisition: TruBridge
IKS Health Vision FY 2030
| 2 Crores | LTM December 2025 | FY 30 |
|---|---|---|
| EBITDA | ≈ 1000 | ≈ 3000 |
| Net Debt | ≈ 300 | Similar to Dec 2025 |
IKS
Technology advancement
Proposed Acquisition of ARAI
ARAI - Founding team
Dr. Asoke Talukder
Co-Founder & CEO
Adi Faculty, GSE, NTK Surathkal
Dr Asoke Kumar Talukder is a serial entrepreneur and polymath. He is a Physicist by training, Data Scientist by choice, and Biomedical Scientist by passion.
He has contributed significantly to the field of Artificial Intelligence, Data Sciences, Omic sciences, Systems Biology, Knowledge engineering, Mobile computing and Information Security
He has worked in India, USA, UK, and Singapore in the domains of Product Innovation for companies like ICL, Fujitsu-ICIM, Microsoft, Oracle, Informix, Digital, Hewlett Packard, Sequoia, Northern Telecom, NEC, KredietBank, iGate, Cellnext, Tyfone etc.
He is the author / editor six books and has published 80+ peer reviewed research papers.
Dr. Roland Haas
Co-Founder & CEO
Professor at IITB
Born and raised in Germany, Dr. Haas studied Computer Science, Mathematics, and Electrical Engineering and has more than 30 years of experience across techno - managerial, research, and BD positions in Europe, USA, and Asia.
He is also an expert reviewer for cybersecurity of critical infra.
His teaching and research interests cover AI/ML, Gen AI, Deep Learning, Cyber-Physical Systems, Cybersecurity, Autonomous Systems,, Healthcare AI and Clinical Decision Support Systems. He is the author of four books and has published 80+ peer reviewed research papers
IKS
24
IKS Health AI Strategy and the Gap
IKS is executing a strong AI roadmap — with ARAI, we will rely much lesser on third party models
What IKS Already Has
- Agentic AI platform built on Google Cloud / Gemini
- Scribble Suite — ambient AI scribe (Epic-integrated, KLAS #1 2026)
- AI-driven RCM coding: 89% automation, 88%+ accuracy
- Human-in-the-loop model for compliance & accuracy
- Investments in other AI accelerators
- 2025 Google Cloud DORA Award for AI augmentation
- Black Book #1: AI-driven RCM, clinical documentation (12 years)
The Gap — What ARAI Brings
- Accelerates IKS’s AI R&D with expertise to build models for RCM (denials prediction)
- AI models that enable humans to understand, trust & interpret the output — thereby building trust through transparency
- Knowledge graph IP for clinical reasoning
- Clinical Decision Support Systems (CDSS)
- Secure and Robust AI with reduced hallucination
- Scalable R&D talent pipeline and mentorship
Buy Vs Build - Accelerating Time to Market
Acquisition Price
$1.2M in upfront cash for acquiring the IP
Discounted ESOPs over 4 years to align long term interest
Build Vs. Buy - Cost Avoidance Analysis
| $8–12M
Estimated Build Cost
(Internal Engineering) | 2–3 Yrs
Time-to-Parity if all the Knowledge
Graphs are Built Internally | 30% Increase in efficiency
Reduction in number of tokens to
achieve the same objective |
| --- | --- | --- |
ARAI's IP slot directly into three revenue-generating AI workstreams already under development
| Autonomous Medical Coding
$15–25M
Addressable Annual Revenue | Denials Prediction & Prevention
30–40%
Reduction in Denial Rates | Clinical Decision Support Products
12–18 Mo
Faster Time to Market |
| --- | --- | --- |
LKS
Joint Value Proposition: IKS + ARAI + TruBridge
One Integrated System - Compounding Value creation
| SYSTEM OF RECORD
(Stores the record) | INTELLIGENCE LAYER
(Makes it smart) | SYSTEM OF ACTION
(Makes it actionable) |
| --- | --- | --- |
| TruBridge EHR
Via EHR + Services
WHAT IT DOES
The trusted clinical record market leader for rural and community hospitals — patient history, orders, medications, diagnoses.
- Live clinical data
- Leading EHR vendor for rural and community hospitals
- Being upgraded to modern tech stack in 18 months | ARAI Solutions
AI Brain
WHAT IT DOES
Peer-reviewed clinical AI that understands medical relationships and validates every decision before it acts.
- Proprietary Knowledge Graphs provide intelligent reasoning layer that checks AI outputs against medical knowledge
- ARAI’s Clinical Ontology layer differentiates IKS as a full-stack company with proprietary domain intelligence | IKS Health
Care Enablement Platform
WHAT IT DOES
The operating layer that takes clinical data and turns it into completed tasks — billing, prior authorizations, documentation, coding.
- 600+ clients across multiple service lines, 24% revenue growth
- Handles the full care journey — both acute and ambulatory
- Agentic AI with a Human in the Loop model |
WHAT THIS CREATES TOGETHER
For Hospitals
One system that holds their patient records and handles their admin — billing, coding, prior auth — automatically, with no extra software vendors to manage.
For Physicians
AI that documents visits, surfaces missed diagnoses, and checks prescriptions in real time — giving time back to patient care without changing clinical workflows.
For IKS Shareholders
A defensible platform business: 2,000+ healthcare organizations, owned AI IP, and revenue expansion opportunities as customers gravitate towards an integrated System of Action & Record provider
IKS
26
IKS CARES FOUNDATION
IKS CARES FOUNDATION
2025-26: A Story of Expansion
- With a focus on constantly improving access to quality primary healthcare for underprivileged communities, IKS Cares Foundation has been expanding its scope of work – to cover a wider range of health needs, beneficiaries, and geographies.
- Newly added in 2025-26: Dental Health Camps & Expansion into Telangana
Anemia in Women & Children
Diabetes in Adults
Dental Care for All Ages (Onsite)
Maharashtra
Telangana
IKS CARES
29
IKS CARES FOUNDATION
More than doubling the impact in FY2025-26
- From 15,118 screenings in it's first year and a half of existence, IKS Cares has screened over 30,000 children and adults in FY25-26 alone
- In addition, live, on-site dental treatment addresses a huge unmet need
IKS CARES
IKS CARES FOUNDATION
Key Programs: Mumbai and Hyderabad
Free Mobile Clinics for Anemia and Diabetes - Mobile clinics, led by IKS's medical personnel, offer the latest diagnostic facilities, physical examination by our doctors, free medication, and follow up checks.
Free Mobile Dental Health - IKS's dentists deliver live, on-site treatment in the form of ultra-sound scaling, filling of primary cavities, fluoride based preventive care, and free medication for pain and infections.
Diagnostic Support Services - To conduct basic haematological investigations to diagnose Anemia and Diabetes; To screen children for oral health and provide dental care treatment on-site - a vast unmet need across India.
Patient Education - To raise awareness about preventive healthcare issues and the importance of dental hygiene
Integration - To integrate patients into existing programs
Curative Healthcare - To prescribe and dispense medicines for common ailments
Follow-up Care - To ensure that the prescribed medication doses are being provided and taken according to the schedule. To check for improvement in status post-medication.
IKS CARES
IKS CARES FOUNDATION
Medical Camps: Impact as of end March 2026
194
MEDICAL CAMPS
of which 112 were in FY25-26
45577
SCREENED
As of March, 2026.
15931
DIAGNOSED AS ANEMIC
110+
FOLLOW-UP CAMPS
Follow Up & Medications Provided
73%
Children Positively Impacted
42%
Children Moved From Anemic To Non-Anemic Level
IKS CARES
IKS CARES FOUNDATION
Dental Camps: Impact as of end March 2026
15
DENTAL CAMPS
1789
DENTAL SCREENINGS
As of March, 2026.
915
DENTAL TREATMENTS
- Complete oral health assessment
- Ultrasonic scaling (Cleaning of teeth)
- Filling primary cavities: GIC & Composite Restorations
- Fluoride based preventive treatments
- Medications for pain, infection management
IKS CARES
IKS CARES FOUNDATION
Thank You
IKS HEALTH